Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery

Executive Summary

The discovery of metabotropic glutamate receptors in the early '90s opened up a new world of potential drug targets in CNS diseases and beyond. But targeting specific mGluRs proved difficult; eventually the challenge of designing selective molecules led to breakthroughs modulating receptors at sites distinct from the endogenous binding site. This so-called allosteric modulation may help to clear a logjam of undruggable GPCRs and other receptors. Creating drug-like molecules remains a challenge but industry, after some false starts, is poised to make advances as compounds begin to hit proof-of-concept in man.

You may also be interested in...



Getting Through To Autism: Seaside Pioneers New Drugs

Tiny Seaside Therapeutics is doing pioneering work to develop disease-modifying drugs for Autism Spectrum Disorders, a group of syndromes that not long ago was thought immutable and even blamed on bad parenting. By targeting molecular pathways associated with the single gene disorder fragile X syndrome, Seaside hopes to extrapolate its work to other “autisms” and help people most affected by those disorders learn to walk, talk, or even live independent lives.

Lilly Pulls The Plug On Next-Gen Antipsychotic

With one Phase III trial failed and a second halted for futility, Eli Lilly calls it quits on pomaglumetad methionil, a compound the pharma had hoped would succeed blockbuster antipsychotic Zyprexa, marking the end of the road for a pioneering compound in the effort to drug metabotropic glutamate receptors (mGluRs), a promising class for CNS therapies.

Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators

With 15 programs in various stages of early development, the Swiss biotech ratchets up the emphasis on partnering to gain back support and non-dilutive capital after the failure of its lead compound.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel